Vanda Pharmaceuticals' (VNDA) MAA for Fanaptum in Schizophrenia Accepted for Evaluation by EMA

Go back to Vanda Pharmaceuticals' (VNDA) MAA for Fanaptum in Schizophrenia Accepted for Evaluation by EMA

European Medicines Agency Accepts Fanaptum® (iloperidone) Marketing Authorization Application for the Treatment of Schizophrenia in Adults

December 22, 2015 4:30 PM EST

WASHINGTON, Dec. 22, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that its Marketing Authorization Application (MAA) for oral Fanaptum® tablets has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of schizophrenia in adults.

"The MAA validation demonstrates Vanda's commitment to offer another option to the healthcare community to treat a severe, disabling mental disorder," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "This continues our efforts to expand the availability of iloperidone to people who we believe would benefit... More